Second External Quality Assurance Study for the Serological Diagnosis of Hantaviruses in Europe by Escadafal, Camille et al.
Second External Quality Assurance Study for the
Serological Diagnosis of Hantaviruses in Europe
Camille Escadafal
1,2*, Tatjana Avs ˇic ˇ-Z ˇupanc
3, Olli Vapalahti
4, Bo Niklasson
5,6, Anette Teichmann
1,
Matthias Niedrig
1, Oliver Donoso-Mantke
1
1ZBS-1, Robert Koch Institute, Berlin, Germany, 2European Public Health Microbiology Training Programme (EUPHEM), European Centre for Disease Prevention and
Control (ECDC), Solna, Sweden, 3Institute of Microbiology & Immunology, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia, 4Department of Virology,
Haartman Institute, University of Helsinki, Helsinki, Finland, 5Apodemus AB, Stockholm, Sweden, 6Department of Medical Cell Biology, Uppsala University, Uppsala,
Sweden
Abstract
Hantaviruses are endemic throughout the world and hosted by rodents and insectivores. Two human zoonoses,
hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS), are caused by hantaviruses and
case fatality rates have reached 12% for HFRS and 50% for HPS in some outbreaks. Symptomatic hantavirus infections in
Europe are summarised as HFRS mainly due to Puumala, Dobrava-Belgrade and Saaremaa virus. While HFRS has an overall
low incidence in Europe, the number of cases varies from 100 per year in all Eastern and Southern Europe up to 1,000 per
year only in Finland. To assess the quality of hantavirus diagnostics, the European Network for the Diagnostics of
‘‘Imported’’ Viral Diseases (ENIVD) organised a first external quality assurance (EQA) in 2002. The purpose of this second EQA
study is to collect updated information on the efficiency and accurateness of hantavirus serological methods applied by
expert laboratories. A serum panel of 14 samples was sent to 28 participants in Europe of which 27 sent results. Performance
in hantavirus diagnosis varied not only on the method used but also on the laboratories and the subclass of antibodies
tested. Commercial and in-house assays performed almost equally. Enzyme immunoassays were mainly used but did not
show the best performances while immunoblot assays were the less employed and showed overall better performances.
IgM antibodies were not detected in 61% of the positive IgM samples and IgM detection was not performed by 7% of the
laboratories indicating a risk of overlooking acute infections in patients. Uneven performances using the same method is
indicating that there is still a need for improving testing conditions and standardizing protocols.
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Introduction
Hantaviruses are endemic throughout the world and naturally
hosted by rodents and insectivores. Humans are mostly infected by
inhalation of virus-containing aerosolized excretions (urine, saliva
or feces) or bites from host rodents, and there is no transmission
between humans. Two human zoonoses, hemorrhagic fever with
renal syndrome (HFRS) and hantavirus pulmonary syndrome
(HPS), are caused by hantavirus infections and case fatality rates
can reach up to 50% for Sin Nombre and New York virus
infections causing HPS and 12% for hantavirus infections causing
HFRS. Nevertheless, the vast majority of human hantavirus
infections are asymptomatic.
HPS are reported mainly in the Americas while symptomatic
hantavirus infections in Europe are summarised as HFRS which
occurs mainly due to infections by Puumala virus (PUUV) carried
by Myodes glareolus (bank vole), Dobrava-Belgrade virus (DOBV)
carried by Apodemus flavicollis (yellow-necked mouse) and Saaremaa
virus (SAAV or DOBV-A.a) carried by Apodemus agrarius (striped
field mouse) [1,2,3,4,5,6]. The clinical picture is variable and
depends largely on the strain of the infecting virus. HFRS is
characterized by fever, acute renal failure, haemorrhage, hypo-
tension, and vascular leakage. HFRS has a low incidence in most
of Europe. Nevertheless, a survey conducted by Heyman and
Vaheri in 2007, accounted for a total of 35,424 confirmed cases in
all Europe. Of the total number of cases, 24,672 (70%) were
reported by Finland while no hantavirus cases were reported from
Spain, Italy, Cyprus or Denmark [7].
Despite numerous research efforts, there is still no safe and
effective vaccine or specific antiviral treatment against hantavirus
infections.
Hantavirus infections were probably highly under-diagnosed
before reliable diagnostic tools became available in the 1990s. Due
to the short-term and difficult detection of virus and viral nucleic
acid in infected humans, the diagnostics of human hantavirus
infections is mainly based on serological assays. For many years,
the serological diagnosis of hantavirus infections was mainly based
on immunofluorescence assays. However, in the recent years,
enzyme-linked immunosorbent assays, immunoblotting, and
immunochromatographic rapid tests have been developed [8].
The diagnosis is often made with in-house or commercial tests
undergoing internal evaluation [9].
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European Network for Diagnostics of ‘Imported’ Viral Diseases
(ENIVD) (http://www.enivd.org) organised a first external quality
assurance (EQA) study in 2002 with 18 laboratories participating
[10]. No other EQA was performed since and little information is
available concerning the overall and relative proficiency of
hantavirus serology in different laboratories. For this reason, a
second EQA was organised by the end of 2010 and a serum panel
of 14 samples were sent to 28 participants all across Europe to be
tested of the presence of antibodies.
Materials and Methods
Participants
A total of 28 laboratories involved in diagnostics of hantavirus
infections were invited to participate in this study. Invitees are
members of the European Network for the Diagnostics of
‘Imported’ Viral Diseases-Collaborative Laboratory Response
Network (ENIVD-CLRN) or national/regional reference labora-
tories for hantaviruses or vector-borne diseases. The study was
announced as an EQA study on hantavirus serological diagnostic
methods proficiency, which included publishing the results in a
comparative and anonymous manner.
The ENIVD-CLRN coordinated this EQA as in other
previously performed EQA studies [11,12].
Specimen preparation
A panel of 14 samples was prepared with anti-hantavirus
positive sera from seven patients infected with hantavirus diluted
with fresh frozen plasma previously confirmed as negative for
hantavirus. After dilution, the samples were heat inactivated
(56uC, 1 h). Aliquots of 100 ml were number-coded, freeze dried
for 24 h (Christ, AlphaI-5, Hanau, Germany) and stored at 4uC
until dispatch.
All sera used in the panel come from an already-existing
collection of patient sera from routine laboratory investigations.
Sera samples were taken with the written consent from the patients
and all samples were anonymized.
The proficiency panel was composed of (Table 1):
N a set of 6 positive samples consisting of serial 2-fold dilutions of
a Puumala positive serum from Sweden (IgM and IgG positive)
N one serum from Slovenia positive for Puumala (IgM negative,
IgG positive)
N one serum from Slovenia positive for Puumala (IgM and IgG
positive)
N one serum from Slovenia positive for Dobrava-Belgrade (IgM
negative, IgG positive)
N one serum from Slovenia positive for Dobrava-Belgrade (IgM
and IgG positive)
N one serum from Finland positive for Puumala (IgM positive,
IgG positive)
N one antiserum containing antibodies reactive for inner cell
structures as specificity control
N one negative serum from Finland as negative control
N one sample with plasma used for dilution as negative control
Validation and dispatch of the panel sets
Before shipping, the serum panel was evaluated by two expert
laboratories. The testing methods used included in house IFA and
ELISA as well as commercial IFA.
The EQA panels were distributed to participants with full
instructions. Samples were shipped by normal post at ambient
temperature to the participating laboratories. We requested
participant laboratories to resuspend the samples in 100 mlo f
water and to analyse the material as serum samples for detection of
IgM and IgG antibodies against hantaviruses. They were asked to
report their results and any problems encountered as well as
information on the protocol details using a common formulary
included in the documentation.
Evaluation of the results
To guarantee anonymous participation, an individual numerical
identification code was assigned to the results reported by each
laboratory. This number was followed by a letter (A, B, C) when
different data sets of results based on different methods were sent.
Author Summary
Hantaviruses are endemic throughout the world and
naturally hosted by rodents. The vast majority of human
hantavirus infections are asymptomatic. In Europe, symp-
tomatic hantavirus infections are summarised as hemor-
rhagic fever with renal syndrome (HFRS) mainly due to
Puumala, Dobrava-Belgrade and Saaremaa virus. HFRS can
cause fever, headache, and flank and abdominal pain.
Moreover, renal dysfunction can lead to acute renal failure.
Despite numerous research efforts, there is still no safe and
effective vaccine or specific antiviral treatment against
hantavirus infections. In this context, an accurate diagnosis
as well as a reliable surveillance of hantavirus infections is
essential. The diagnostics of hantavirus infections are
based on serology using in-house or commercial assays. To
assess the quality of hantavirus diagnostics, the European
Network for the Diagnostics of ‘‘Imported’’ Viral Diseases
organised a first external quality assurance (EQA) in 2002.
In this publication we describe a second EQA study
launched in 2011 with the objective to collect updated
information on the efficiency and accurateness of hanta-
virus serological methods applied by expert laboratories.
The study shows uneven performances indicating that
there is still a need for improving testing conditions and
standardizing protocols.
Table 1. Composition of the EQA panel.
sample n6 #13 #2 #12 #6 #14 #8 #9 #11 #4 #10 #1 #3 #7 #5
virus type PUU PUU PUU PUU PUU PUU PUU PUU DOB DOB PUU neg neg neg
dilution none 1:2 1:4 1:8 1:16 1:32 1:10 1:10 1:10 1:10 none none 1:10 1:10
IgM/IgG +/++ /++ /++ /++ /++ /++ /+ 2/++ /+ 2/++ /+ 2/22 /22 /2
PUU: Puumala; DOB: Dobrava-Belgrade; neg: negative control.
doi:10.1371/journal.pntd.0001607.t001
EQA Study for Hantaviruses Diagnosis
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We assigned one point for correct virus type and one point for
correct positive or negative result whereas false- negatives/
positives results were not scored. Equivocal or borderline results
were considered as positive. IgM and IgG results were considered
separately. Data collected were entered into Microsoft Excel
(Microsoft Corp., Bellingham, WA, USA).
Results
Among the 28 invitees, the following 27 laboratories coming
from 20 countries of the European region sent back their results
(total of 33 data sets) and participated to the EQA:
Medical University of Vienna, Austria; Institute of Tropical
Medicine, Antwerp, Belgium; Reference Laboratory for Vector-
Borne Diseases, Brussels, Belgium; National Reference Vector-
borne infections and leptospirosis laboratory, Sofia, Bulgaria;
National Reference Laboratory for Arboviruses, Ostrava, Czech
Republic; National Institute for Health Development, Virology
Department, Tallinn, Estonia; Institut Pasteur, Department of
Virology, Lyon, France; Institut fu ¨r Medizinische Virologie, Berlin,
Germany; Friedrich-Loeffler-Institut, Greifswald, Germany;
EUROIMMUN AG, Lu ¨beck, Germany; Institut fu ¨r Mikrobiologie
der Bundeswehr, Munich, Germany; Firm Mikrogen, Neuried,
Germany; National Reference Laboratory for Viral Zoonoses,
Budapest, Hungary; National Institute for Infectious Diseases,
Rome, Italy; Microbiologia e Biotecnologie mediche Universita `d i
Padova, Italy; Policlinico San Matteo, Pavia, Italy; Infectiology
Centre of Latvia, Riga, Latvia; Laboratoire National de Sante ´,
Luxembourg, Luxembourg; Norwegian Institute of Public Health
Department of Virology, Oslo, Norway; National Institute of
Health, A ´guas de Moura, Portugal; Laboratory for Vector-Borne
Infections and Medical Entomology, Bucharest, Romania; Univer-
sity of Ljubljana Medical Faculty, Ljubljana, Slovenia; Centro
Nacional de Microbiologı ´a Instituto de Salud Carlos III, Madrid,
Spain; Spiez Laboratory, Spiez, Switzerland; Erasmus MC
Department of Virology, Rotterdam, the Netherlands; Refik
Saydam National Public Health Agency, Ankara, Turkey; Refer-
ence Unit Centre for Emergency Preparedness and Response,
Wiltshire, United Kingdom.
Of all data sets of results received, 46% (15/33) reported the use
of enzyme-linked immunosorbent assays (EIA), 27% (9/33)
immunofluorescence assays (IFA), 15% (5/33) immunoblot assays
(IBA) and 12% (4/33) EIA combined EIA with IBA or IFA.
Participants used mainly commercial tests (24/33, 73%) and the
remaining tests were in house methods. The performance of
commercial tests was equal to that of in-house methods for both
IgM and IgG detection.
Performances varied depending not only on the diagnostic
method used but also on the laboratory performing the test and
the subclass of antibodies detected by the test. Two out of 33
reports (6%) did not include IgM testing results and tested only for
the presence of IgG antibodies by IFA (Table 2). On the other
hand, all laboratories have tested for the presence of IgG
antibodies (Table 3). Out of the 33 data sets obtained, about half
(48%) did not report virus type specific results as they only tested
for the presence or not of antibodies against hantavirus infection.
We can have indications on the specificity of the diagnostic
methods looking at the testing results of the two negative controls
and the unspecific serum. Concerning IgM antibody detection,
only one false positive result was obtained with an in-house IFA in
the negative control containing the plasma used for dilution
(sample #7). Concerning IgG antibody detection, false positives
were observed in the specificity control, sample #5 (one positive
and one borderline result, 6% of all results). Surprisingly more
false positives were observed among the two negative controls,
samples #3 and #7 (2 positive and 2 borderline results for the
dilution serum, sample #7, 12% of all results; 1 positive and 1
borderline result for the negative serum, sample #3, 6% of all
results). False positives results were all obtained by commercial
IFA or EIA.
To have indications on the specificity of the methods used we
can also compare between the different strains of hantavirus by
virus type or by place of origin. Comparing the DOBV and
PUUV positive sera, we observe that the DOBV positive serum
was detected more accurately by IgM detection methods than by
IgG detection contrary to the PUUV sera. In fact only two of the
31 methods used for IgM detection (6,5%) have failed to detect
anti-DOBV IgM while 14 of the 33 methods used for IgG
detection (42%) have failed to detect anti-DOBV IgG in sample
#10.
Comparing the detection of PUUV positive sera by country of
origin (Sweden, Finland and Slovenian strains), no main
differences in performance were observed for IgM or IgG
antibody detection.
We can have indications on the sensitivity of the diagnostic
methods looking at the testing results of the 6 serial dilutions of
PUUV positive sera (samples #13, 2, 12, 6, 14 and 8). Regarding
the testing of IgM antibodies, at least one false negative was
reported by all participants except one (97%). The only method
which presented no false negatives in its results was a combination
of in house EIA and IFA. In contrast, IgG testing has shown to be
more sensitive as half of the results for IgG detection did not report
false negatives. All IBA results revealed no false negatives in IgG
detection and thus showed to be very sensitive. IFA showed lower
performance concerning sensitivity of IgG detection (5 tests of 9
reported false negatives, 56%) and EIA showed the lowest
performance in this regard (11 tests of 15 reported false negatives,
73%). In house versus commercial assays showed similar
sensitivities regarding IgG detection. Only 2 diagnostic methods
(6%) failed in the detection of IgG antibodies in the highest PUUV
sera dilution (sample #13) and both were commercial EIAs.
Comparing the scores obtained by the participants and the
sensitivity of the tests for IgG detection, it seems that better
performances were achieved by the laboratories using IBA which
were all commercial assays (5 recomLine Bunyavirus IgM/IgG
from Mikrogen and 1 Euroline Hantavirus profil global from
Euroimmun). The first EQA study run in 2002 had shown similar
good performances for commercial IBAs. No major differences
were found in terms of performance concerning IgG/IgM
antibody detection with IFA or EIA.
Discussion
Although most of the participants used EIA, these tests have not
shown the best performances concerning both specificity and
sensitivity characteristics.
Among all participants, two have not included the detection of
IgM antibodies in their routine diagnosis algorithm (6%).
Furthermore the proportion of samples correctly diagnosed for
IgM detection (271/434, 62%) was much lower than the
proportion of samples with an accurate IgG antibody diagnosis
(406/462, 88%). These elements indicate a risk of overlooking
acute infections in patients with early hantavirus infections. In fact
the sole presence of IgG antibodies in a serum sample could be the
sign of previous contact with hantaviruses and is not enough to
prove a recent infection. To confirm the diagnosis, the analysis of a
second sample is required. Differences of test sensitivity depending
EQA Study for Hantaviruses Diagnosis
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first hantavirus EQA study [10] as well as in EQA studies for the
serological diagnostic of other viruses [11,12,13]. Nevertheless low
sensitivity for IgM detection is especially observed in samples with
higher dilutions of the PUUV positive serum from Sweden
(samples #12, #6, #14 and #8). Therefore, the high amount of
false negatives can be attributed to very low concentrations of IgM
antibodies in these samples.
Regarding strain typing, it is important to point out that,
because of the scoring system used in this EQA, the laboratories
reporting lower scores are not necessarily the ones with lower
performances. In fact, data sets reporting correct positive and
negative results but not specifying the strain type obtain rather low
scores although the diagnostic is entirely correct. These results are
completely satisfactory in the context of clinical diagnosis as there
is no specific treatment for the different hantavirus infections. The
most important information is whether the patient is diagnosed
positive for hantavirus or not and further analyses can always be
performed. On the other hand information on the strain type is
relevant for surveillance activities.
Although HFRS has a low incidence in most of Europe, the
disease can be very severe. Therefore, the sensitivity of the tests
Table 2. EQA results with IgM detection methods.
sample n6
Lab n6 method #13 #2 #12 #6 #14 #8 #9 #11 #4 #10 #1 #3 #7 #5 score
20 EIA*/IFA* P+ P+ P+ P+/2 P+ P+/2 P+ neg D+ neg P+ neg neg neg 23
4 EIAu P+/D+ neg P+ P+/2 P+/2 neg P+/2 neg D+ neg P+/2 neg neg neg 19
15 B IFAu P+ P+ P+ P+ neg neg P+ neg D+ neg P+ neg neg neg 19
1 A EIAu P+ P+ P+/2 P+ neg neg P+/2 neg neg neg P+/2 neg neg neg 17
16 B IFAu P+ P+/2 P+/2 neg neg neg neg neg D+ neg P+/2 neg neg neg 15
24 IFAu/IBAu P+ D+ neg D+ neg neg P+ neg D+ neg P+ neg neg neg 15
27 IFA* P+ P+ neg neg neg neg P+ neg D+ neg P+ neg neg neg 15
5 A IFAu neg H+ H+ H+ H+ neg H+ neg H+ neg H+ neg neg neg 12
12 IFAu H+ H+ H+ H+ neg neg H+ neg H+ neg H+ neg neg neg 12
21 IFAu H+ H+ H+ H+/2 H+/2 neg neg neg H+ neg H+ neg neg neg 12
6 EIAu/IFAu P+/2 neg neg neg neg neg P+/2 neg D+ neg neg neg neg neg 11
15 A IBAu P+/D+ neg neg neg neg neg P+/2 neg D+ neg neg neg neg neg 11
16 C IBAu P+ P+ neg neg neg neg neg neg D+ neg neg neg neg neg 11
23 EIA*/IFA* H+ H+/2 H+/2 neg neg neg H+/2 neg H+ neg H+/2 neg neg neg 11
5 B EIA* H+/2 neg neg neg neg neg H+ neg H+ neg H+/2 neg neg neg 9
9I B A u neg neg neg neg neg neg P+ neg D+ neg neg neg neg neg 9
11 IBAu neg neg neg neg neg neg P+ neg H+/D+ neg neg neg neg neg 9
26 IBAu neg neg neg neg neg neg P+/2 neg D+/2 neg neg neg neg neg 9
28 EIAu H+ H+ neg neg neg neg neg neg H+ neg H+ neg neg neg 9
14 EIAu H+ H+ neg neg neg neg neg neg H+ neg neg neg neg neg 8
7 EIAu H+ neg neg neg neg neg H+ neg H+ neg neg neg neg neg 8
18 EIAu H+/2 neg neg neg neg neg H+/2 neg H+ neg neg neg neg neg 8
2 EIAu P+ neg neg neg neg neg neg neg neg neg neg neg neg neg 7
16 A EIAu H+/2 neg neg neg neg neg neg neg H+ neg neg neg neg neg 7
19 EIA* neg neg neg neg neg neg neg neg D+ neg neg neg neg neg 7
22 EIAu H+/2 neg neg neg neg neg neg neg H+ neg neg neg neg neg 7
1 B EIAu neg neg neg neg neg neg neg neg H+ neg neg neg neg neg 6
10 EIAu neg neg neg neg neg neg neg neg H+ neg neg neg neg neg 6
13 EIAu neg neg neg neg neg neg neg neg H+ neg neg neg neg neg 6
17 EIAu neg neg neg neg neg neg neg neg H+ neg neg neg neg neg 6
25 IFA* neg neg H+ neg neg neg neg neg H+ neg H+ neg H+ neg 6
3 IFA* N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. 0
8 IFA* N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. 0
EIA: enzymatic immunofluorescence assay; IFA: immunofluorescence assay; IBA: immunoblot assay.
neg: negative result; N.A.: not available;
*: in house assay;
u: commercial assay.
P: Puumala virus; D: Dobrava-Belgrade virus; H: hantavirus.
bold: correct result; normal: incorrect result.
doi:10.1371/journal.pntd.0001607.t002
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negatives may be considered more critical than reporting a false
positive as positive results can always be submitted to further
testing for confirmation. In other words, in case of low disease
prevalence, the predictive value of a negative test (PVN) should be
higher than the predictive value of a positive test (PVP), meaning
the proportion of non affected people among those tested negative
should be higher than the proportion of affected people among
those tested positive.
Overall, commercial and in-house assays performed almost
equally. The method used (EIA, IFA or IBA) was not the main
factor to have impact on the quality of the test results. From the
results of this EQA, it appears clearly that the quality of the results
is mostly linked to the laboratories and their use of the different
protocols since their performance differ greatly even when using
the same techniques. Such problems could be solved by the
standardisation of the protocols and controls used and the
optimisation of conditions during testing.
The previous hantavirus EQA performed in 2002 [10] also
concluded that the nature of the test (in-house or commercial; IFA,
EIA or IBA) used by the participants seemed to have only little
influence on the performance of the diagnostic. However, IBA
Table 3. EQA results with IgG detection methods.
sample n6
Lab n6 method #13 #2 #12 #6 #14 #8 #9 #11 #4 #10 #1 #3 #7 #5 score
9I B A u all + all + all + all + all + P+ P+ P+ D+ D+ P+ neg neg neg 25
11 IBAu P/D+ P/D+ P/D+ P/D+ P/D+ P/D+ P+ P+ H/D+ H/D+ P+ neg neg neg 25
15 A IBAu P/D+ P/D+ P/D+ P/D+ P+/2 P+/2 P+ P+ D+ D+ P+ neg neg neg 25
15 B IFAu P+ P+ P+ P+ P+ P+ P+ P+ D+ D+ P+ neg neg neg 25
16 B IFAu P+ P+ P+ P+ P+ P+ P+ P+ D+ D+/2 P+ neg neg neg 25
16 C IBAu all + all + all + P+ P+ P+ P/SN+ P+ D+ D+ P+ neg neg neg 25
20 EIA*/IFA* P+ P+ P+ P+ P+ P+ P+ P+ D+ D+ P+ neg neg neg 25
6 EIAu/IFAu P+ P+ P+ P+ P+ P+/2 P+ P+ D+ H+/2 P+ neg neg neg 24
26 IBAu P/D+ P/D+ H+ P+ P+/2 P+/2 P+ P+ D+/2 D+/2 P+ neg neg neg 24
27 IFA* P+ P+ P+ P+ P+/2 P+ P+ P+ D+ neg P+ neg neg neg 23
8 IFA* P/D+ P/D+ P/D+ P+ P+ P+ P+ P+ D+ neg P+ neg neg neg 23
3 IFA* P+ P+ P+ P+ P+ P+ P+ neg SE+ neg P+ neg neg neg 20
24 IFAu/IBAu P+ D+ P+ D+ P+ D+ P+ P+ D+ H+ P+ neg H+ neg 20
1 A EIAu P+ P+ P+ P+/2 P+ P+ P+ neg neg neg P+ neg neg P+/2 18
4 EIAu neg H+ P+ P+ neg P+/2 P+ neg D+ neg P+ neg neg neg 16
23 EIA*/IFA* H+ H+ H+ H+ H+ neg P+ P+ H+ H+ P+ neg neg neg 16
12 IFAu H+ H+ H+ H+ H+ H+ H+ H+ H+ H+ H+ neg neg neg 14
14 EIAu H+ H+ H+ H+ H+ H+ H+ H+ H+ H+/2 H+ neg neg neg 14
16 A EIAu H+ H+ H+ H+ H+ H+/2 H+ H+ H+ H+ H+ neg neg neg 14
19 EIA* H+ H+ H+ H+ neg H+/2 H+ H+ D+ H+ H+ neg neg neg 14
28 EIAu H+ H+ H+ H+ H+ H+ H+ H+ H+ H+/2 H+ neg neg neg 14
5 B EIA* H+ H+ H+ H+ H+ H+/2 H+ H+/2 H+ neg H+ neg neg neg 13
18 EIAu H+ P+ H+ H+ H+/2 neg H+ H+/2 P+ neg H+ neg neg neg 13
21 IFAu H+ H+ H+ H+ H+ H+ H+ H+ H+ H+ H+ neg H+/2 neg 13
5 A IFAu H+ H+ H+ H+ H+ H+ H+ H+ H+ H+ H+ H+ H+ neg 12
10 EIAu H+ H+ H+ H+ H+/2 neg H+ H+ H+ neg H+ neg neg neg 12
25 IFA* H+ H+ H+ H+ H+ H+ H+ H+ H+ neg H+ H+ neg neg 12
7 EIAu H+ H+ H+ H+ neg neg H+ H+ H+ neg H+ neg neg neg 11
13 EIAu H+ H+ H+ H+/2 H+/2 neg H+ neg H+ neg H+ neg neg neg 11
22 EIAu H+ H+ H+ H+ H+ neg H+ H+ H+ H+ H+ H+/2 H+/2 neg 11
17 IFA* H+ H+ H+ H+ neg neg H+ neg H+ neg H+ neg neg neg 10
2 EIAu P+ neg neg neg neg neg neg neg neg neg P+ neg neg neg 7
1 B EIAu neg neg neg neg H+/2 H+/2 neg neg H+/2 neg neg neg neg H+ 5
EIA: enzymatic immunofluorescence assay; IFA: immunofluorescence assay; IBA: immunoblot assay.
neg: negative result; N.A.: not available;
*: in house assay;
u: commercial assay.
P: Puumala virus; D: Dobrava-Belgrade virus; SN: Sin Nombre; SE: Seoul virus; H: hantavirus.
bold: correct result; normal: incorrect result.
doi:10.1371/journal.pntd.0001607.t003
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18 laboratories participating to the 2002 EQA also took part at the
second EQA (lab nu1, 10, 11, 13, 20 and 25). Two of them have
improved their percentage of correct results, two of them have
shown similar performance and two have decrease their
performance.
Further external quality controls should be performed for
hantavirus detection as EQAs are not only important for the most
prevalent viral pathogens but also for rarely suspected viruses.
Performing EQAs on a regular basis enables to ensure the
reliability of diagnostic results, to guarantee a continuous quality of
the existing diagnostic methods and further improve them.
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